熱門資訊> 正文
Turnstone Biologics将被Xoma Royalty收购
2025-06-27 20:00
- XOMA Royalty (NASDAQ:XOMA), a biotech royalty acquirer based in Emeryville, California, has agreed to buy cancer drug developer Turnstone Biologics (NASDAQ:TSBX) for $0.34 per share in cash plus a contingent value right (CVR), the companies announced Friday.
- The merger transaction has also received the backing of some of Turnstone's stockholders, with investors holding nearly 25% of company stock signing agreements in support of the deal, which is expected to close in August.
- Under the agreement, XOMA Royalty (NASDAQ:XOMA) will initiate a tender offer to buy all outstanding shares of Turnstone (NASDAQ:TSBX) common stock.
- XOMA is expected to acquire Turnstone immediately after closing the tender offer, with all remaining shares not tendered in the offer getting converted into rights to receive the same cash consideration and the nontransferable CVR.
More on XOMA, Turnstone Biologics
- XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
- XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M
- Seeking Alpha’s Quant Rating on XOMA
- Historical earnings data for XOMA
- Financial information for XOMA
推薦文章
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
美股機會日報 | 6月CPI符合預期！英偉達盤前漲超4%，今夜有望再創新高
華盛早報丨突發！特朗普100%關税劍指俄羅斯，歐盟720億歐元反制美國商品；黃仁勛年內第三次來華，出席鏈博會
美股機會日報 | 史上首次！比特幣升破12萬美元；馬斯克：特斯拉年底會有「史詩級震撼」的演示
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
